Literature DB >> 29626240

Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.

Won Hwa Kim1,2, Nariya Cho3,4,5, Young-Seon Kim1,6, Ann Yi7,8.   

Abstract

OBJECTIVES: To evaluate the changes in mammographic density after tamoxifen discontinuation in premenopausal women with oestrogen receptor-positive breast cancers and the underlying factors
METHODS: A total of 213 consecutive premenopausal women with breast cancer who received tamoxifen treatment after curative surgery and underwent three mammograms (baseline, after tamoxifen treatment, after tamoxifen discontinuation) were included. Changes in mammographic density after tamoxifen discontinuation were assessed qualitatively (decrease, no change, or increase) by two readers and measured quantitatively by semi-automated software. The association between % density change and clinicopathological factors was evaluated using univariate and multivariate regression analyses.
RESULTS: After tamoxifen discontinuation, a mammographic density increase was observed in 31.9% (68/213, reader 1) to 22.1% (47/213, reader 2) by qualitative assessment, with a mean density increase of 1.8% by quantitative assessment compared to density before tamoxifen discontinuation. In multivariate analysis, younger age (≤ 39 years) and greater % density decline after tamoxifen treatment (≥ 17.0%) were independent factors associated with density change after tamoxifen discontinuation (p < .001 and p = .003, respectively).
CONCLUSIONS: Tamoxifen discontinuation was associated with mammographic density change with a mean density increase of 1.8%, which was associated with younger age and greater density change after tamoxifen treatment. KEY POINTS: • Increased mammographic density after tamoxifen discontinuation can occur in premenopausal women. • Mean density increase after tamoxifen discontinuation was 1.8%. • Density increase is associated with age and density decrease after tamoxifen.

Entities:  

Keywords:  Breast density; Mammography; Prognosis; Receptors, Oestrogen; Tamoxifen

Mesh:

Substances:

Year:  2018        PMID: 29626240     DOI: 10.1007/s00330-017-5293-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.

Authors:  Sarah J Nyante; Mark E Sherman; Ruth M Pfeiffer; Amy Berrington de Gonzalez; Louise A Brinton; Erin J Aiello Bowles; Robert N Hoover; Andrew Glass; Gretchen L Gierach
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

Review 2.  Analysis of mammographic density and breast cancer risk from digitized mammograms.

Authors:  J W Byng; M J Yaffe; R A Jong; R S Shumak; G A Lockwood; D L Tritchler; N F Boyd
Journal:  Radiographics       Date:  1998 Nov-Dec       Impact factor: 5.333

3.  Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study.

Authors:  P C Stomper; B J Van Voorhis; V A Ravnikar; J E Meyer
Journal:  Radiology       Date:  1990-02       Impact factor: 11.105

4.  Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern.

Authors:  M B Laya; J C Gallagher; J S Schreiman; E B Larson; P Watson; L Weinstein
Journal:  Radiology       Date:  1995-08       Impact factor: 11.105

5.  Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.

Authors:  Anne McTiernan; Rowan T Chlebowski; Christopher Martin; Jennifer David Peck; Aaron Aragaki; Etta D Pisano; C Y Wang; Karen C Johnson; Joann E Manson; Robert B Wallace; Mara Z Vitolins; Gerardo Heiss
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.

Authors:  Jingmei Li; Keith Humphreys; Louise Eriksson; Gustaf Edgren; Kamila Czene; Per Hall
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

7.  Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.

Authors:  Kyung Lan Ko; In Suk Shin; Ji Young You; So-Youn Jung; Jungsil Ro; Eun Sook Lee
Journal:  Breast Cancer Res Treat       Date:  2013-12       Impact factor: 4.872

8.  Age-related difference in tamoxifen disposition.

Authors:  F Peyrade; M Frenay; M C Etienne; F Ruch; C Guillemare; E François; M Namer; J M Ferrero; G Milano
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

10.  Change of mammographic density predicts the risk of contralateral breast cancer--a case-control study.

Authors:  Maria E C Sandberg; Jingmei Li; Per Hall; Mikael Hartman; Isabel dos-Santos-Silva; Keith Humphreys; Kamila Czene
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

View more
  2 in total

Review 1.  Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review.

Authors:  Paola Oceguera-Basurto; Antonio Topete; Antonio Oceguera-Villanueva; Jorge Rivas-Carrillo; Marco Paz-Davalos; Antonio Quintero-Ramos; Alicia Del Toro-Arreola; Adrián Daneri-Navarro
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

2.  Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.

Authors:  Linda Thorén; Mikael Eriksson; Jonatan D Lindh; Kamila Czene; Jonas Bergh; Erik Eliasson; Per Hall; Sara Margolin
Journal:  Breast Cancer Res Treat       Date:  2021-09-27       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.